<?xml version="1.0" encoding="UTF-8"?>
<p>Acute hepatic injury has been reported, most often in MERS. In one Saudi cohort, 22/70 patients (31.4%) suffered from liver dysfunction during their illness (Saad 
 <italic>et al</italic>. 
 <xref rid="bib52" ref-type="bibr">2014</xref>). In a separate MERS cohort of critically ill patients, as many as half of these patients exhibited elevated aminotransferases during their ICU stay (Arabi 
 <italic>et al</italic>. 
 <xref rid="bib3" ref-type="bibr">2014</xref>). Although liver dysfunction has been reported in COVID-19 patients, its prevalence seems much lower; only 3/80 (3.75%) of patients in a Chinese cohort showed abnormal liver enzymes, and it should be further noted that this proportion was even lower than that in Wuhan (Wu 
 <italic>et al</italic>. 
 <xref rid="bib71" ref-type="bibr">2020</xref>).
</p>
